Vaccines against the arthropod-borne dengue virus (DENV) are still commercially nonexistent. A subunit immunization strategy may be of value, especially if a safe viral vector acts as a biologically active adjuvant. The DENV envelope protein (E), the main target for neutralizing immune responses, has three conformational domains. The immunoglobulin-like and independently folding domain III (DIII) contains epitopes that elicit highly specific neutralizing antibodies.
Download count: 0
- Partial requirement for: M.S., Arizona State University, 2015Note typethesis
- Includes bibliographical references (pages 84-87)Note typebibliography
- Field of study: Biology